Abstract
This study evaluates the effectiveness of immunomodulating drug isoprinosine in a comprehensive treatment of genital warts in men. Most of the patients were aged 20-30 years. The combination therapy was found to have long term effectiveness. In the group of patients undergoing only destructive methods of treatment relapse after 8 month follow-up was diagnosed in 32% and in patients of the combination therapy group (destruction plus isoprinosine) - in 7% of patients. The pharmacological action of the drug (immunostimulating, antiviral) and the effectiveness of its combination with destructive therapies justify the use of inosine pranobex (isoprinosine) both in the complex therapy of genital warts and for the prevention of the disease recurrence.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / adverse effects
-
Adjuvants, Immunologic / therapeutic use*
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Combined Modality Therapy
-
Condylomata Acuminata / drug therapy*
-
Condylomata Acuminata / immunology
-
Condylomata Acuminata / surgery
-
Condylomata Acuminata / virology
-
Drug Therapy, Combination
-
Genital Diseases, Male / drug therapy*
-
Genital Diseases, Male / immunology
-
Genital Diseases, Male / surgery
-
Genital Diseases, Male / virology
-
Humans
-
Inosine Pranobex / administration & dosage
-
Inosine Pranobex / adverse effects
-
Inosine Pranobex / therapeutic use*
-
Male
-
Papillomavirus Infections / drug therapy*
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / surgery
-
Papillomavirus Infections / virology
-
Treatment Outcome
-
Young Adult
Substances
-
Adjuvants, Immunologic
-
Antiviral Agents
-
Inosine Pranobex